SOURCE: DNAPrint Genomics, Inc.

September 26, 2007 07:00 ET

DNAPrint® Genomics Founder and Chief Scientific Officer Publishes Book on Molecular Photofitting

"Molecular Photofitting; Predicting Ancestry and Phenotype Using DNA" by Dr. Tony Frudakis Details How Physical Descriptions of Individuals Can Be Generated Using Only Their DNA

SARASOTA, FL--(Marketwire - September 26, 2007) - DNAPrint® Genomics (OTCBB: DNAG) today announced that the Company's Founder and Chief Scientific Officer, Dr. Tony Frudakis, has written a book entitled "Molecular Photofitting; Predicting Ancestry and Phenotype Using DNA," published by Elsevier Academic Press.

In the field of forensics, there is a critical need for genetic tests that can function in a predictive or inferential sense, before suspects have been identified, and/or for crimes for which DNA evidence exists but eye-witnesses do not. Dr. Frudakis' book fills this need by describing the process of generating a physical description of an individual from the analysis of his or her DNA. The molecular photofitting process has been used to assist with the identification of remains and to guide criminal investigations toward certain individuals within the sphere of prior suspects.

The book was derived from DNA Print Genomics' pioneering research in Molecular Photofitting and is the first book of its kind that illustrates the topic of Genomic Ancestry estimation or Phenotype Inference.

"This book essentially provides a usable guide for both the forensic scientist hoping to make use of the new tests becoming available, and for the human genetic researcher working to discover the panels of markers that comprise these tests," said Dr. Frudakis. "By fulfilling population structure as a practical forensics and clinical genomics tool, this book serves to redefine the way science and history look at ancestry and genetics, and shows how these tools can be used to amplify the efficacy of our criminal justice system."

Molecular Photofitting; Predicting Ancestry and Phenotype Using DNA retails for $99.95. To order online, please visit:

DNAPrint™ Genomics, Inc.

DNAPrint™ Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    Ron Stabiner
    The Wall Street Group, Inc.